JHBP (CY) HOLDINGS LIMITED Inactive Instrument
JHBP (CY) Holdings Limited Stock Hong Kong S.E.
Equities
6998
KYG6501A1013
Biotechnology & Medical Research
| Sales 2021 | - | Sales 2022 | 15.93M 2.2M 17.22M 3.01M | Capitalization | 1.17B 162M 1.27B 221M |
|---|---|---|---|---|---|
| Net income 2021 | -865M -119M -935M -163M | Net income 2022 | -730M -101M -789M -138M | EV / Sales 2021 | - |
| Net cash position 2021 | 2.14B 296M 2.32B 405M | Net cash position 2022 | 1.56B 215M 1.69B 295M | EV / Sales 2022 | -24.3 x |
| P/E ratio 2021 |
-3.28
x | P/E ratio 2022 |
-1.62
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 66.55% |
More Fundamentals
* Assessed data
More news
Genor Biopharma Holdings Ltd, formerly JHBP CY Holdings Ltd, is China-based company mainly engaged in the research and development of biopharmaceutical products. The Company focuses on the development and commercialization of oncology and autoimmune drugs. The Company's main drugs include lerociclib (GB491), coprelotamab (GB221), geptanolimab (GB226), GB492, GB242 and GB223. The Company mainly conducts its businesses in the China market.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
